firazorexton   Click here for help

GtoPdb Ligand ID: 12603

Synonyms: TAK-994 (firazorexton sesquihydrate)
Compound class: Synthetic organic
Comment: Firazorexton (TAK-994) is a selective OX2 orexin receptor agonist (700-fold selectivity) [2]. Note that TAK-994 refers to a sesquihydrate formulation of firazorexton.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 6
Hydrogen bond donors 2
Rotatable bonds 7
Topological polar surface area 95.09
Molecular weight 470.51
XLogP 0.63
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES CC(C)(C(=O)N1CC[C@@H]([C@@H]1CC2=CC=CC(=C2F)C3=CC(=CC(=C3)F)F)NS(=O)(=O)C)O
Isomeric SMILES CC(C)(C(=O)N1CC[C@@H]([C@@H]1CC2=C(C(=CC=C2)C3=CC(=CC(=C3)F)F)F)NS(=O)(=O)C)O
InChI InChI=1S/C22H25F3N2O4S/c1-22(2,29)21(28)27-8-7-18(26-32(3,30)31)19(27)11-13-5-4-6-17(20(13)25)14-9-15(23)12-16(24)10-14/h4-6,9-10,12,18-19,26,29H,7-8,11H2,1-3H3/t18-,19-/m0/s1
InChI Key VOSAWOSMGPKQEQ-OALUTQOASA-N
No information available.
Summary of Clinical Use Click here for help
Firazorexton (TAK-994) was advanced to clinical trials to evaluate its effectiveness to treat narcolepsy but Takeda announced that they were discontinuing its development in October 2021 [3]. Their two phase 2 studies were terminated in October 2021 in response to an adverse hepatotoxicity signal, however final analysis of results was published in mid-2023 [1]. TAK-994 was associated with improved daytime wakefulness and reduced cataplexy rates in patients with narcolepsy type 1, which confirms the need to develop better tolerated OX2 receptor agonists to meet the needs of these patients.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04096560 A Study of TAK-994 in Adults With Type 1 and Type 2 Narcolepsy Phase 2 Interventional Takeda The TAK-994-1501 study 1
NCT04820842 A Study of TAK-994 in Adults With Narcolepsy Phase 2 Interventional Takeda The TAK-994-1504 study 1